| Characteristic, % | Na | PD-L1 TC ≥ 25% (n = 132) | PD-L1 TC < 25% (n = 264) |
|---|
| Median age, years (range) | | 62.0 (38.0–87.0) | 62.0 (28.0–93.0) |
| < 60 | 167 | 32.9 | 67.1 |
| ≥ 60 | 228 | 33.8 | 66.2 |
| Sex |
| Male | 317 | 30.9 | 69.1 |
| Female | 79 | 43.0 | 57.0 |
| Race |
| Caucasian | 339 | 32.7 | 67.3 |
| Black or African American | 20 | 30.0 | 70.0 |
| Asian | 22 | 50.0 | 50.0 |
| Region |
| United States | 205 | 29.3 | 70.7 |
| Asia | 22 | 50.0 | 50.0 |
| Europe | 169 | 36.1 | 63.9 |
| ECOG PS |
| 0 | 73 | 50.7 | 49.3 |
| 1 | 87 | 32.2 | 67.8 |
| ≥ 2 | 41 | 26.8 | 73.2 |
| Tobacco use |
| Current | 97 | 26.8 | 73.2 |
| Former | 199 | 32.2 | 67.8 |
| Never | 78 | 42.3 | 57.7 |
| Alcohol consumption |
| Current | 148 | 26.4 | 73.6 |
| Former | 123 | 32.5 | 67.5 |
| HPV status |
| Positive | 37 | 21.6 | 78.4 |
| Negative | 93 | 25.8 | 74.2 |
| Timing of tissue sample extraction |
| Pre-1st chemotherapy, % | 202 | 30.2 | 69.8 |
| Post-1st chemotherapy, % | 36 | 25.0 | 75.0 |
| Type of tumor sample |
| Surgical resection | 186 | 34.9 | 65.1 |
| Surgical biopsy | 199 | 32.2 | 67.8 |
| Punch biopsy | 8 | 12.5 | 87.5 |
| Location of tumor sample |
| Primary tumor | 153 | 34.0 | 66.0 |
| From recurrent disease | 175 | 32.6 | 67.4 |
| From metastatic disease | 80 | 33.8 | 66.3 |
| Primary tumor site | | 132 | 261 |
| Oral cavity | 108 | 43.5 | 56.5 |
| Oropharynx | 61 | 34.4 | 65.6 |
| Hypopharynx | 21 | 9.5 | 90.5 |
| Larynx | 99 | 30.3 | 69.7 |
| Overlapping lesion | 22 | 22.7 | 77.3 |
| Stage at index dateb |
| Stage 0–III | 17 | 29.4 | 70.6 |
| Stage IVA | 62 | 37.1 | 62.9 |
| Stage IVB | 21 | 23.8 | 76.2 |
| Stage IVC | 230 | 31.3 | 68.7 |
| Time from diagnosis to index |
| Median, months (range) | | 11.4 (0.0–475.9) | 14.7 (0.0–349.8) |
| Sites of new metastases post index date |
| Local lymph node | 89 | 31.5 | 68.5 |
| Lung | 77 | 27.3 | 72.7 |
| Bone | 29 | 37.9 | 62.1 |
| Distant lymph node | 23 | 34.8 | 65.2 |
| Liver | 23 | 30.4 | 69.6 |
| Skin/soft tissue | 21 | 42.9 | 57.1 |
| Head and neck | 11 | 27.3 | 72.7 |
| Pleura | 9 | 44.4 | 55.6 |
- aPatients with PD-L1 result N = 396
- bIndex date is defined as date of diagnosis of R/M HNSCC not amenable to local therapy
- ECOG PS Eastern Cooperative Oncology Group performance status, HNSCC head and neck squamous cell carcinoma, HPV human papilloma virus, mo months, PD-L1 programmed cell death-ligand 1, R/M recurrent and/or metastatic, TC tumor cell
